Trial Profile
An Open-label, Multi-center, Global, Rollover Study for Patients Who Have Previously Been Treated With Capmatinib (INC280) as Monotherapy or in Combination in a Novartis Sponsored Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary) ; Gefitinib; Nazartinib; Osimertinib
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 29 Sep 2022 Time frame for primary outcome increased from 5 years to 10 years. Osimertinib drug added newly to intervention.
- 17 Jul 2020 Planned End Date changed from 31 Jul 2027 to 30 Jul 2027.
- 17 Jul 2020 Planned primary completion date changed from 31 Dec 2020 to 30 Jul 2027.